|
Emerging Therapies in Respiratory Disease
11th
September 2007 |
|
| Programme: | |
| 09.00 | Registration and Coffee |
| 09.50 | Introduction - Dr A J Ratcliffe, UCB |
| Session 1. Chair: Dr Ruth Lock | |
| 10.00 |
Prof Clive Page, King's College Challenges facing the development of new drugs for the treatment of airway diseases |
| 10.50 |
Prof Chris O'Callaghan, University of
Leicester Drug delivery to the lungs: problems and opportunities |
| 11.45 |
Dr Douglas Ferguson, AstraZeneca Mechanisms of Drug Retention in the Lung |
| 12.30 | Lunch |
| Session 2. Chair: Dr Steve Collingwood | |
| 13.20 |
Dr Fredrick Van Goor, Vertex
Pharmaceuticals, USA Pharmacological rescue of mutant CFTR function for the treatment of cystic fibrosis |
| 14.00 |
Dr Richard Hale, Cellzome A potent and selective Histamine H4 receptor antagonist for the treatment of allergic rhinitis |
| 14.50 |
Dr Robin Fairhurst, Novartis
Institutes for Biomedical Research The Identification of Inhaled Once-Daily Long-Acting β2-Adrenoceptor Agonists for the Treatment of Asthma and COPD |
| 15.30 | Tea |
| Session 3. Chair: Dr A J Ratcliffe, UCB | |
| 16.00 |
Dr Hamish Ryder, Almirall,
Spain Discovery and early development of aclidinium bromide, a new long acting muscarinic antagonist for COPD |
| 16.40 |
Dr Keith Biggadike, GSK Novel Glucocorticoids |
| 17.30 | Close |
| Home / Meetings / Membership / Student Bursaries / Administration / History of the SMR / SMR Award / Archive Material / Links / Contact Us |